, /PRNewswire/ -- Contact Information:     Laurence Rosen, Esq.     Phillip Kim, Esq.     The Rosen Law Firm, P.A.     275 Madison Avenue, 40th Floor     New York, NY 10016     Tel: (212) 686-1060     Toll Free: (866) 767-3653     Fax: (212) 202-3827 Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both ...

Core Viewpoint - A class action lawsuit has been filed against Molina Healthcare, Inc. on behalf of shareholders who purchased or acquired its securities between February 5, 2025, and July 23, 2025, indicating potential legal challenges for the company [1]. Company Summary - Molina Healthcare, Inc. is identified as a health insurance company [1]. - The lawsuit suggests that there may be significant concerns regarding the company's operations or disclosures during the specified class period [1].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming December 2, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Molina Healthcare, Inc. ("Molina†or the "Company†) (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR MOLINA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO. ...

NEW YORK--(BUSINESS WIRE)---- $MOH #BFA--Molina Healthcare, Inc. investors that lost money are notified to contact BFA Law before the December 2, 2025 securities fraud class action deadline. ...

Group 1 - S&P 500 health care stocks, including Centene (CNC) and Molina Healthcare (MOH), experienced an increase after President Trump indicated a willingness to negotiate with Democrats to prevent the expiration of enhanced ACA subsidies [1] - Wells Fargo analysts now assume that the ACA subsidies will continue, contingent on Democrats agreeing to end the government shutdown [1] - Oscar Health's stock has shown improved price performance, resulting in an upgrade to its IBD Relative Strength Rating from 80 to 87 [2]

Core Viewpoint - The Molina Healthcare class action lawsuit alleges that the company and its executives failed to disclose significant adverse information regarding its financial health and operational challenges during the specified class period, leading to substantial losses for investors [4][5][6]. Group 1: Class Action Details - The class action lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and covers purchasers of Molina Healthcare securities from February 5, 2025, to July 23, 2025 [1]. - Investors have until December 2, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims violations of the Securities Exchange Act of 1934 by Molina Healthcare and its top executives [1]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina Healthcare failed to disclose material adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [4]. - It is claimed that Molina's near-term growth relied on reduced utilization of behavioral health, pharmacy, and inpatient and outpatient services [4]. - The lawsuit asserts that Molina's financial guidance for fiscal year 2025 was likely to be cut due to these undisclosed issues [4]. Group 3: Financial Impact and Stock Performance - On July 7, 2025, Molina reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [5]. - Following this announcement, Molina's stock price fell significantly, reflecting investor concerns over the company's financial outlook [5]. - On July 23, 2025, Molina further cut its full-year 2025 earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year [6]. - The stock price reportedly dropped nearly 17% after this news, indicating a strong negative market reaction [6]. Group 4: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Molina securities during the class period to seek lead plaintiff status [7]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [7]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [8].

Group 1 - The article discusses an opportunity for investors in Molina Healthcare, Inc. to lead a securities fraud lawsuit with the Schall Law Firm [1] - The focus is on potential legal actions related to securities fraud, indicating a significant concern among investors regarding the company's practices [1] - The involvement of the Schall Law Firm suggests a structured approach to addressing investor grievances and pursuing legal remedies [1]

Core Viewpoint - Molina Healthcare, Inc. is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Group 1 - The lawsuit has been initiated by the DJS Law Group, indicating potential legal challenges for the company [1] - The allegations pertain to securities law violations, which could lead to significant financial repercussions for Molina Healthcare [1]

Core Viewpoint - The lawsuit claims that the defendants made false statements regarding Molina's business and prospects, leading to inflated stock prices [1] Group 1 - The lawsuit alleges that the defendants issued misleading information about Molina's operations [1] - The false statements are said to have resulted in the company's stock trading at artificially high prices [1]

Core Viewpoint - A class action lawsuit has been filed against Molina Healthcare, Inc. for allegedly misleading investors regarding its financial performance and medical cost trends during the specified class period from February 5, 2025, to July 23, 2025 [1][5]. Financial Performance - On July 7, 2025, Molina announced second quarter 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [3]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, revising it from at least $24.50 per share to a range of $21.50 to $22.50 [3]. - On July 23, 2025, Molina reported a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year, and further reduced its full-year 2025 adjusted earnings guidance to no less than $19.00 per diluted share, representing a 13.6% cut [4]. - The full-year 2025 GAAP net income guidance was cut by 27% to $912 million, attributed to a challenging medical cost trend environment [4]. Stock Market Reaction - Following the July 7 announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [3]. - After the July 23 announcement, the stock price dropped by $32.03, or 16.84%, closing at $158.22 per share [4]. Allegations in the Lawsuit - The lawsuit alleges that Molina's management made materially false and misleading statements and failed to disclose adverse facts about the company's medical cost trend assumptions and financial guidance [5][6]. - Specific allegations include the failure to disclose the dislocation between premium rates and medical cost trends, and that Molina's near-term growth relied on low utilization of various health services [5].